Yicheng Zhang
Tongji Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yicheng Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05334823 · A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsChongqing Precision Biotech Co., Ltd · recruiting · Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 12:22 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med · 20184,679 citationsRCR 163.2
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.J Clin Oncol · 2021259 citationsRCR 13.2
- 251 citationsRCR 12.2
- 229 citationsRCR 8.6
- 200 citationsRCR 6.9
- Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.Am J Hematol · 2018113 citationsRCR 4.3
- 107 citationsRCR 5.4
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.Blood Cancer J · 2022102 citationsRCR 6.3
- 88 citationsRCR 2.4
- 87 citationsRCR 4.9